UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection

Journal of medical economics, 2016-10, Vol.19 (10), p.983-994

2016

Volltextzugriff (PDF)

Liver-specific case fatality due to chronic hepatitis C virus infection: A systematic review

Annals of hepatology, 2015-09, Vol.14 (5), p.618-630

2015

Volltextzugriff (PDF)

Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies

Cancer biology & therapy, 2018-07, Vol.19 (7), p.636-643

2018

Volltextzugriff (PDF)

Comparative Effectiveness of Long‐Acting Beta2‐Agonist Combined with a Long‐Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease

Pharmacotherapy, 2017-04, Vol.37 (4), p.447-455

2017

Volltextzugriff (PDF)

Retracted Publications in the Drug Literature

Pharmacotherapy, 2012-07, Vol.32 (7), p.586-595

2012

Volltextzugriff (PDF)

Economic Evaluation of the Impact of Medication Errors Reported by U.S. Clinical Pharmacists

Pharmacotherapy, 2014-04, Vol.34 (4), p.350-357

2014

Volltextzugriff (PDF)

Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan

Journal of medical economics, 2016-12, Vol.19 (12), p.1144-1156

2016

Volltextzugriff (PDF)

Predicting Acute Exacerbations in Chronic Obstructive Pulmonary Disease

Journal of managed care & specialty pharmacy, 2018-03, Vol.24 (3), p.265-279

2018

Volltextzugriff (PDF)

Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β 2 -Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid

The Annals of pharmacotherapy, 2017-11, Vol.51 (11), p.945-953

2017

Volltextzugriff (PDF)

Patient health utility, work productivity, and lifestyle impairment in chronic hepatitis C patients in France

Clinics and research in hepatology and gastroenterology, 2015-06, Vol.39 (3), p.307-314

2015

Volltextzugriff (PDF)

Comparative Effectiveness of Long-Acting Beta 2 -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease

Pharmacotherapy, 2017-04, Vol.37 (4), p.447-455

2017

Volltextzugriff (PDF)

Costs and absence of HCV-infected employees by disease stage

Journal of medical economics, 2015-09, Vol.18 (9), p.691-703

2015

Volltextzugriff (PDF)

Association Between Cognitive Function and Health Care Costs 3 Months and 6 Months After Initiating Antidepressant Medication for Depressive Disorders

Journal of managed care & specialty pharmacy, 2015-09, Vol.21 (9), p.742-752

2015

Volltextzugriff (PDF)

Clinical Benefits of Achieving Deep Remission to Second-Line Therapy in Patients with Relapse/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) - a Real-World Study

Blood, 2017-12, Vol.130, p.2130-2130

2017

Volltextzugriff (PDF)

Drivers of Treatment Patterns in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with B-Cell Receptor Inhibitors (BCRis) — a Medical Chart Review Study

Blood, 2017-12, Vol.130, p.4681-4681

2017

Volltextzugriff (PDF)

Comparative Effectiveness of Long-Acting Beta sub(2)-Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease

Pharmacotherapy, 2017-04, Vol.37 (4), p.447-455

2017

Volltextzugriff (PDF)

Economic Evaluation of the Impact of Medication Errors Reported by U . S . Clinical Pharmacists

Pharmacotherapy, 2014-04, Vol.34 (4), p.350-357

2014

Volltextzugriff (PDF)

Comparative Efficacy and Safety of Combination Treatments for Chronic Obstructive Pulmonary Disease

Samp, Jennifer C

2017

Volltextzugriff (PDF)

Discovery of N–X anomeric amides as electrophilic halogenation reagents

Nature chemistry, 2024-05, Vol.16 (9), p.1539-1545

2024

Volltextzugriff (PDF)

Molecular matched targeted therapies for primary brain tumors—a single center retrospective analysis

Journal of neuro-oncology, 2022-09, Vol.159 (2), p.243-259

2022

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(20)
Dissertationen
(1)

Sprache

Englisch
(21)
Japanisch
(2)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection

Liver-specific case fatality due to chronic hepatitis C virus infection: A systematic review

Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies

Comparative Effectiveness of Long‐Acting Beta2‐Agonist Combined with a Long‐Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease

Retracted Publications in the Drug Literature

Economic Evaluation of the Impact of Medication Errors Reported by U.S. Clinical Pharmacists

Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan

Predicting Acute Exacerbations in Chronic Obstructive Pulmonary Disease

Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β 2 -Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid

Patient health utility, work productivity, and lifestyle impairment in chronic hepatitis C patients in France

Comparative Effectiveness of Long-Acting Beta 2 -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease

Costs and absence of HCV-infected employees by disease stage

Association Between Cognitive Function and Health Care Costs 3 Months and 6 Months After Initiating Antidepressant Medication for Depressive Disorders

Clinical Benefits of Achieving Deep Remission to Second-Line Therapy in Patients with Relapse/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) - a Real-World Study

Drivers of Treatment Patterns in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with B-Cell Receptor Inhibitors (BCRis) — a Medical Chart Review Study

Comparative Effectiveness of Long-Acting Beta sub(2)-Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease

Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study

Economic Evaluation of the Impact of Medication Errors Reported by U . S . Clinical Pharmacists

Comparative Efficacy and Safety of Combination Treatments for Chronic Obstructive Pulmonary Disease

Discovery of N–X anomeric amides as electrophilic halogenation reagents

Molecular matched targeted therapies for primary brain tumors—a single center retrospective analysis

Suchergebnisse filtern